IP Library Granted Patent US 9,915,658
Granted Patent B2
US 9,915,658 · App. 14/982,015 · Granted Mar 13, 2018

Reagents for HCV antigen-antibody combination assays

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,915,658
App. No.
14/982,015
Granted
Mar 13, 2018
Kind
B2
Abstract

The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens.

Claims (13)

1. An immunoassay for simultaneously detecting HCV antigens and antibodies in a sample, comprising:

providing a non-ionic detergent Lauryldimethylamine N-oxide (LDAO), a first pair of a capture antigen and a detection antigen, a first pair of a capture antibody and a conjugate antibody, wherein said capture antigen and said detection antigen both comprise a first peptide fragment of a first HCV protein, said capture antibody and said conjugate antibody specifically bind to a second HCV protein, and said detection antigen and said conjugate antibody comprise one and same signal generating means;

contacting said sample in the presence of said detergent with said capture antigen, said detection antigen, said capture antibody and said conjugate antibody, to form a sandwich complex between said capture antigen, said detection antigen, and an anti-HCV antibody present in said sample, and a complex between said capture antibody, said conjugate antibody, and an HCV antigen present in said sample; and

measuring a signal generated from said signal-generating means as a result of the formation of said complexes, thereby simultaneously detecting HCV antigens and antibodies in said sample.

2. The immunoassay of claim 1 , wherein said first HCV protein and second HCV protein are independently selected from the group consisting of the core antigen, E1, E2, NS2, NS3, NS4, and NS5.

3. The immunoassay of claim 1 , wherein said first HCV protein and said second HCV protein are the same, and said capture antibody and said conjugate antibody bind to a region of said second HCV protein outside of said first peptide fragment.

4. The immunoassay of claim 3 , wherein said first HCV protein and said second HCV protein are both the HCV core antigen.

5. The immunoassay of claim 1 , wherein a second pair of a capture antigen and a detection antigen is provided, wherein said capture antigen and said detection antigen of the second pair both comprise a second peptide fragment of an HCV protein, wherein said second peptide fragment is different from said first peptide fragment.

6. The immunoassay of claim 1 , wherein said capture antibody in said first pair comprises two or more antibodies.

7. The immunoassay of claim 1 , wherein a second pair of a capture antibody and a conjugate antibody is provided, wherein said capture antibody and said conjugate antibody in said second pair specifically bind to said second HCV protein or a different HCV protein.

8. The immunoassay of claim 1 , wherein said capture antigen and said capture antibody are attached to a solid phase.

9. The method of claim 1 , wherein LDAO is present in the range of 0.1 to 2.0%.

10. The method of claim 9 , wherein LDAO is present in the range of 0.3 to 1.0%.

Assignments (6)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC
Reel/Frame 060219/0571 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
SECURITY AGREEMENT Recorded Nov 6, 2018
From: ORTHO-CLINICAL DIAGNOSTICS, INC.
To: BARCLAYS BANK PLC
Reel/Frame 047435/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2018
From: ZHENG, JIAN; YANG, JIANPING
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 044966/0632 →